Serine-threonine kinase ROCK2 regulates germinal center B cell positioning and cholesterol biosynthesis

Germinal center (GC) responses require B cells to respond to a dynamic set of intercellular and microenvironmental signals that instruct B cell positioning, differentiation, and metabolic reprogramming. RHO-associated coiled-coil–containing protein kinase 2 (ROCK2), a serine-threonine kinase that can be therapeutically targeted by ROCK inhibitors or statins, is a key downstream effector of RHOA GTPases. Although RHOA-mediated pathways are emerging as critical regulators of GC responses, the role of ROCK2 in B cells is unknown. Here, we found that ROCK2 was activated in response to key T cell signals like CD40 and IL-21 and that it regulated GC formation and maintenance. RNA-Seq analyses revealed that ROCK2 controlled a unique transcriptional program in GC B cells that promoted optimal GC polarization and cholesterol biosynthesis. ROCK2 regulated this program by restraining AKT activation and subsequently enhancing FOXO1 activity. ATAC-Seq (assay for transposase-accessible chromatin with high-throughput sequencing) and biochemical analyses revealed that the effects of ROCK2 on cholesterol biosynthesis were instead mediated via a novel mechanism. ROCK2 directly phosphorylated interferon regulatory factor 8 (IRF8), a crucial mediator of GC responses, and promoted its interaction with sterol regulatory element–binding transcription factor 2 (SREBP2) at key regulatory regions controlling the expression of cholesterol biosynthetic enzymes, resulting in optimal recruitme...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research

Related Links:

Authors: Dashti-Khavidaki S, Khalili H, Nourian A Abstract Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and modification of COVID-19 treatment, drug interactions, nephrotoxicity of drugs that are used for treatment of COVID-19 and potential risks/benefits of routine medications of CKD patients during COVID-19 pandemic. CKD patients should be treated according to local or national COVID-19 protocols as other patients. Bu...
Source: Iranian Journal of Kidney Diseases - Category: Urology & Nephrology Tags: Iran J Kidney Dis Source Type: research
Aggressive lipid-lowering therapy with statins is the generally accepted approach for treating patients with acute coronary syndrome (ACS).1,2 Recently, the findings from studies of patients with ACS who were administered intensive lipid-lowering therapy involving non-statin drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9, that is, PCSK9, inhibitors, showed improved clinical outcomes.3,4 We published results from the Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER) study, a randomized controlled trial which tested th...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Publication date: Available online 11 July 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Ray Subir, Mukherjee Jagat J, Gangopadhyay Kalyan K
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
We were interested to read Nous et al. ’s1 recent article which described the prognostic benefits of using coronary computed tomography angiography (CCTA) to identify subclinical coronary artery disease (CAD) in patients with atrial fibrillation (AF). The addition of the calcium score and CCTA resulted in the re-classification of 47 pa tients’ cardiovascular risk stratification score. Twenty-eight of these moved up in classification with eight becoming very high-risk due to obstructive CAD. Initiation of secondary prevention (statin therapy) in these patients was concluded to be beneficial.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
COVID, sacubitril/valsartan, left atrial appendage occlusion, and statins are the topics Dr John Mandrola discusses in this week ’ s on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news
AbstractRosuvastatin/ezetimibe combines two lipid-lowering agents: rosuvastatin, an HMG-CoA reductase inhibitor (i.e. statin) with particularly strong inhibitory effects on hepatic cholesterol synthesis, and ezetimibe, which inhibits the intestinal absorption of cholesterol. A fixed-dose combination (FDC) of rosuvastatin/ezetimibe is indicated as an adjunctive therapy to diet for the management of primary hypercholesterolemia in adults in numerous countries worldwide. In well-designed clinical trials evaluating the therapeutic efficacy of rosuvastatin/ezetimibe administered as either separate agents or as an FDC, rosuvasta...
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
AbstractIntroductionProprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are proven to have profound lowering of low-density lipoprotein cholesterol (LDL-C) in patients with clinical atherosclerotic cardiovascular disease or familial hypercholesterolemia.AimThe primary purpose of this study was to evaluate PCSK9i utilization in older adults, with a focus on efficacy outcomes within 6  months of initiation. Secondary outcomes included tolerability, out-of-pocket expenses (OPE), and barriers to initiation of therapy.MethodsWe conducted a retrospective chart review of patients ≥ 65 years prescribed P...
Source: High Blood Pressure and Cardiovascular Prevention - Category: Cardiology Source Type: research
Publication date: Available online 8 July 2020Source: Pharmacology &TherapeuticsAuthor(s): Ole Köhler-Forsberg, Christian Otte, Stefan M. Gold, Søren Dinesen Østergaard
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
With trial data for this age group in short supply, a US veterans cohort study saw a 25% drop in all-cause mortality for those newly starting on a statin at age 75 or older.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
People 75 and older who were free of heart disease and prescribed a statin wound up with a 25% lower risk of death from any cause and a 20% lower risk of heart-related death, researchers reported July 7 in the Journal of the American Medical Association.
Source: WebMD Health - Category: Consumer Health News Source Type: news
More News: Biomedical Science | Cholesterol | Statin Therapy